Neuropsychological assessment in HIV/AIDS and its challenges in Galati County

Similar documents
International Symposium on. Barcelona, May 5 th and 6 th 2011

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

Central Nervous System Penetration of ARVs: Does it Matter?

Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV

How to Implement this Assessment in the Clinical Prac5ce?

Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection

DSM-5 and HAND. Diagnosis and Monitoring of HAND 10/6/2015. APA Institute on Psychiatric Services New York City

HIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital

International Forum on HIV and Rehabilitation Research

HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP

HIV & Women: Neurological Issues

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL

HIV associated CNS disease in the era of HAART

Approach to HIV Associated Neurocognitive disorders (HAND)

Opportunistic infections in the era of cart, still a problem in resource-limited settings

HIV Update For the Internist

Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

Report Back from CROI 2010

Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders

Disclosures 12/7/17. UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017

Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection

No Conflict of Interest

Diagnosis and Monitoring of HAND

Learning objectives 6/20/2018

HIV-1 Dual Infection and Neurocognitive Impairment

The prevalence of HIV-associated neurocognitive

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HAND is Common and Important in Patients on ART

HIV and Dementia. London Dementia Clinical Network 14 June Dr Patricia McNamara MB BCh BAO MRCP PhD. Locum Consultant Neurologist, NHNN

Engagement is Key to Effectiveness of Individualized Texting for Adherence Building (itab) Among HIV+ Methamphetamine Users

Aging and Cancer in HIV

The Neurology of HIV Infection. Carolyn Barley Britton, MD, MS Associate Professor of Clinical Neurology Columbia University

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

When to start: guidelines comparison

Clinical notes: Management of HAART in patients with HAND

AIDS 2011, 3, 2011 RW

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain

Case Presentation JF

OPPORTUNISTIC INFECTIONS. Institute of Infectious Diseases, Pune India

Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?

C E L I A J. M A X W E L L, M. D

Complex issues of the late presenter

NeuroAIDS in the modern treatment era

HIV Associated Neurocognitive Disorders in the era of modern CART

Original Article. J Young Pharm, 2016; 8(3): A multifaceted peer reviewed journal in the field of Pharmacy

STRATEGIES FOR MATERNO- FETAL TRANSMISSION OF HIV, HIV AND HBV COINFECTIONS IN CONSTANTA - ROMANIA

May He Rest in Peace

HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS

Valutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND. Workshop Nazionale CISAI Lecco 20 Marzo 2015

HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project

VL patient support: General education at different levels

HAND Diagnostic Issues Addressing Mental Health. Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto St. Michael s Hospital

Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)

natural history of the disease, there is no rationale for limiting screening of cognitive

Housing / Lack of Housing and HIV Prevention and Care

Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona

High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents

Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History

Lifelong Monitoring of HIV-Exposed Uninfected Infants is CRUCIAL! Jennifer Jao, MD, MPH Icahn School of Medicine at Mount Sinai

Cognitive impairment among Indonesia HIV naïve patients

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

Overview on Opportunistic Infections of the Central Nervous System

A challenging neurological complication in a young HIV-infected woman

Dr Ria Daly. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)

HIV Neurology Persistence of Cognitive Impairment Despite cart

Classification of Pediatric HIV CNS Disease: Comparison of CNS and Systemic Disease Markers of Children Treated in the HAART Era

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

HIV coinfection and HCC

HIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London

Epidemiology of HIV Among Women in Florida, Reported through 2014

COGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS PARIYA L. FAZELI

Neurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions

CAREWare Preview Demographics Tab Services Tab Annual Tab RSR Data on Demographic Tab sv

Primary Care for Persons Living with HIV

International Symposium on. Barcelona, May 5 th and 6 th 2011

CAB 59: HIV and neurocogni5ve impairment

UPDATE ON THE CLINICAL MANAGEMENT OF HIV IN BARBADOS

Psychiatric Symptom Burden in Elders with HIV-Associated Neurocognitive Disorders

A Systematic Review of the Screening Accuracy of the HIV Dementia Scale and International HIV Dementia Scale

INTRODUCTION Post-rape HIV acquisition is a huge concern in settings with high prevalence of both HIV and sexual violence. Systematic reviews

Evaluating HIV Clinical Care Quality in the Massachusetts Sites supported through the Medical Case Management System Results from review

Fertility Desires/Management of Serodiscordant HIV + Couples

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Introduction to HIV and Aging

National HIV Nurses Association (NHIVNA) Study Day in collaboration with the British Psychological Society Current Issues in HIV

Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know

DOI: /hiv British HIV Association HIV Medicine (2013), 14, SHORT COMMUNICATION

GLOBAL AIDS MONITORING REPORT

Mortality in HIV Infection: Monitoring Quality Outcomes

Viral hepatitis and Hepatocellular Carcinoma

Study setting. Background and objectives. Associations between sleep parameters,

Action Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)

21 st BHIVA Brighton th April Dr Christopher Wood North Middlesex University Hospital

NEUROCOGNITIVE IMPAIRMENT IN A NEWLY DIAGNOSED HIV POSITIVE PATIENT WITH ADVANCED DISEASE

HIV and Common Comorbidities August 17, Michael MacVeigh, MD & Kristen Meyers, BS, CADC1

Transcription:

Neuropsychological assessment in HIV/AIDS and its challenges in Galati County Manuela Arbune Dunarea de Jos U i e sit Galati București, October 5-6, 2015

Background HAND persists despite ARV (~50%). Neu opatholog i HAART e a: less neuronal loss; gliosis, microglial activation; abnormal protein deposition in brain increased (immune activation, aging); synapto-dendritic damage persists. The phenotype of HAND changed: less opportunistic diseases; less severe dementia with marked motor signs; more milder cognitive disturbances; increasing co-morbid conditions: age related metabolic changes, hypertension, mitochondrial aging, substance abuse, viral co-infections [HCV], toxicity of ARVs.

Objectives To calculate the NCD rate on HIV patients from Galati County by screening tests To compare the dynamic of NCD by screening tests on pediatric and adult epidemic groups To correlate the results of screening tests

Material and Methods Prospective study HIV/AIDS patients recorded in Galati Clinic Screening tests applied in 2 steps: 2010/11 ; 2013/14 3Q test (Simioni) ihds: 4 items (Max 12 p) Depression Beck inventory (borderline 13) Interview based on open question &medical history to identify o neurocognitive confounding factors Severe psychiatric conditions Sequelae from previous CNS-OIs or other neurological diseases Cranial trauma Abuse of psychotropic drugs Alcohol abuse o Co-morbid conditions: HTA, diabetes, dyslipidemia, anemia, hipo-vitamin D ART CNS-effectiveness scores (Letendre S, 2010).

Neurocognitive Impairment: Diagnosis and Management Cranial trauma Severe psychiatric conditions Abuse of psychotropic drugs Alcohol abuse Sequelae from previous CNS-OIs or other neurological diseases

HIV/AIDS EPIDEMIC - GALATI COUNTY Yearly distribution of the new diagnosed cases: 01.12.2014 120 No. patients 110 100 90 80 Peculiarity: 2 Epidemic patterns -pediatric group: cohort (1988-1990) - Adult group: cases infected in adult age No. cumulative cases (1990-2014).... 737 Deaths...... 340 Alive....397 No. Patients with active ARVT....258 70 60 F M 50 40 30 20 10 0 "89 "90 "91 "92 "93 "94 "95 "96 "97 "98 "99 "00 "01 "02 "03 "04 "05 "06 "07 "08 "09 "10 "11 "12 "13 "14 M 1 76 13 17 13 16 22 29 31 27 20 22 16 10 5 8 15 12 7 10 10 7 7 13 12 8 F 45 13 11 8 16 9 11 7 3 7 4 7 0 7 13 14 19 17 16 14 18 15 12 9 9 8 Year

Causes of Deaths in Galati County (2010-2015) Opportunistic Neurologic diseases 4 LEMP diseases 3 Neuro-Toxoplasmosis 3 TB-ME 2 cryptcoccal ME 2 lymphoma 2 brain metastasis (lung cancer) 1 Primary brain tumor 1 bacterial ME 16 Non-Adherent 14-Very Late presenters? How many HAND 2 accidents 2 heart attacks 1 non-aids related cancer 3 Other Opportunistic infection of the central nervous system raised the risk of death more than 5 times. HAND tripled the death risk. Diagnosis of any neurologic disorder doubled the risk of death. P. Vivithanaporn, G. Heo, J. Gamble, H.B. Krentz, A. Hoke, M.J. Gill, C. Power. Neurologic disease burden in treated HIV/AIDS predicts survival: A population-based study. Neurology. 2010; 75: 1150-1158.

Va iatio of Neuro-AID g oup of patie ts 2010 203p 2014 158p 77.3% Follow up the medical care in our clinic 9 2 1 3 10 1 Lost evidence 9 Deaths 8 Prison 3 Spain 3 Italy 10 UK 9 Germany 2 Austria 1 Greece 1

Demographic characteristics Duration of HIV dg.:<5y/5-10y/>10y Pediatric pattern (N=139) 0 /22/129 Adult pattern (N=64) 14/36/14 Χ2-Test P<0.001 2T-Test Median age: 26 [23; 82] Sex: M/F: 99/104 Living area U/R: 102/101 Education level < 4 years: 53/150 Institutionalized Marital status: Single/ Couple Partner status: +/- 26 [24;30] 69/70 68/71 42/97 21/118 75/64 33/16 37 [23; 82] 30/34 34/30 11/53 1/63 19/44 13/19 P<0.001 OR=1.11 ; p=0.71 OR=1.22; p=0.577 OR=2.04; p=0.050 OR=11.21; p=0.003 OR=2.69; p=0.001 OR=3.014; p=0.017 Unknown status of partner Children care 78/125 Smoking 106/97 Alcohol 37/166 15/64 33/106 71/68 26/113 12/44 45/64 35/29 11/53 P=0.651 OR=7.6; p<0.001; OR=1.15; p=0.632 OR=1.10; p=1.794

Characteristics of HIV patients Pediatric pattern Adult pattern (N=139) (N=64) AIDS 169/34 Undetectable ARN-HIV: 136/ 67 HTA 20/183 HCV 3/200 HBV 56/147 126/13 93/ 46 9/130 0/139 51/88 43/21 43/ 21 11/53 3/61 5/59 Nadir CD4 Med=157/mm3 Current CD4 583 /mm3 Δ Cu e t Nadir CD4 : 338/mm3 140/mm3 583 /mm3 372 /mm3 242/mm3 575 /mm3 273 /mm3 2T-Test OR=4.73; p<0.001 OR=0.98; p=0.096 OR=2.99; p=0.017 OR=0; p=0.010 OR=6.83; p<0.001 Mann-Whitney Test P=0.002 P=0.541 P=0.197 Tot. S-Ca Median =9.6mg/dl S-Mg Median=1,98mg/dl Vit D Median=22 mg/dl Triglycerides Median=123 mg/dl Glycemia Median=94.3 mg/dl Hb Median=14.2g/dl 9.69 1.96 21.3 111.8 94.3 14.12 9.45 2.04 17.9 155.6 94.3 14.45 p=0.027 p=0.005 P=0.028 P=0.729 P=0.592 P=0.683

CNS Penetration Scores Of ART 1% 5% 3% 5% 23% 5 6 7 28% 8 9 10 12 35% Letendre CNS score 2010/11 2013/14 N1=203 N2=158 Av=7.86 Med=8 [5;12] Av=8.14 Med=8 [5;12] 61% >7 70.8% >7

Confounding factors/ exclusion criteria 60 50 Exclusion criteria rate 30% (61/ 203) 40 30 20 10 0 Adult Pediatric Low education OI Cranial Trauma Alcohol Severe psihiatric Drugs Hep-C 11 42 6 16 2 7 4 14 3 2 2 1 3 0

The dynamic of NCD screening test (3Q) 75 P<0.001 60 44.6% NCI (2014); 16.8% progressive NCI in the last 2 y P<0.001 +19% 45 30 +16.3% 15 0 3Q-0 3Q-1 Pediatric-I Pediatric -II Adult -I Adult -II 66 23 49 40 34 15 26 23 NCI screening: 3 questions 1. Do you experience frequent memory loss (e.g. do you forget the occurrence of special events even the more recent ones, appointments, etc.)? 2. Do you feel that you are slower when reasoning, planning activities, or solving problems? 3. Do you have difficulties paying attention (e.g. to a conversation, book or movie)? For each question, answers could be: a) never, b) hardly ever, or c) yes, definitely. HIVpositi e pe so s a e o side ed to ha e a a o al esult he a s e i g es, defi itel o at least o e uestio

Depression in HIV patients from Galati 18% 60% 22% NO depression 90 80 70 60 50 40 30 20 10 0 P=0.726 OR=1.18 No depression Transient depression Depression P=0.022 OR=2.821 Pediatric Adult 60 27 Transient depression 21 8 P=0.034 OR=3.346 Depression 11 14 Transient depression: Beck score>13 in one evaluation Depression: Beck score> 13 in both evaluations No depression: Beck score< 13 in both evaluations Challenges: Dep essi e ood is ha gi g alo g the ti e Overlap in signs and symptoms of HIV disease and depression pto s su h as a o e ia, eight loss, fatigue, i so ia diffi ult to att i ute to either depression or HIV/OI

Reasons for depression or transient depression 3%; 2 4%; 3 4%; 3 2%; 2 5%; 4 10%; 8 Single parent 21%;17 Fear of diclosure dg Fear of death 2%; 2 4%; 3 Social reject Partner reject Mourning 10%; 8 Financial Pregnancy 21%; 17 14%; 11 Self image Violence Family reject Depression - Social reject: p=0.005 Transient depression - Partner reject: p=0.028 Median IQ (pediatric) No > Transient > Depression 90.5 > 81.5 > 71.5

Av. Score The Dynamic of ihds Screening Test 4 3.5 3 2.5 2 1.5 1 0.5 0 Median Finger tapping 3.27 2.82 Memory 2010/11 2013/14 3.55 3.43 Coordinating task 3.36 3.1 ihds 2013/14 8.5 9 9.5 10 10.5 2010/11 Av. Score

Comparative Median and Average Scores of HDS Items 4 3.5 3 s c 2.5 o 2 r 1.5 e 1 0.5 0 Memory Finger tapping Pediatric Sequential motor task Adult ihds Score 9.6 9.8 10 10.2 10.4 10.6

Comparative Dynamic of HDS In Pediatric and Adult HIV Groups 75 60 45 30 15 0 P=0.020 Pediatric-I ihds<10 ihds>=10 21 71 22.8% Pediatric II 44 48 47.8% Adult -I Adult -II 19 30 24 25 38.7% 48.9%

No. patients Correlation of 3Q Test and ihds Test 90 80 70 60 50 40 30 20 10 0 P<0.001 OR=4.15 P<0.001 ihds>=10 3Q-0 82 3Q-1 18 ihds-1: >10 (normal) ihds-2: 8-10 (mild disfunction) ihds3: <8 (severe disfunction) ihds (10; 8] 20 18 OR=1.11 P=0.920 ihds<8 1 2

Correlation of ihds and depression 14.00 12.00 HDS 10.00 P=0.902 8.00 P<0.001 6.00 4.00 P< 0.001 2.00 0.00 nu No depression Median HDS 11 T Transient depression 10.5 D Depression 9

Correlations of NCD Tests and HIV Markers ARN-HIV (det/undet)* nadir CD4 3Q-test p=0.151 p=0.300 ihds p=0.677 p=0.020 Depression Transient : OR=3.13; p=0.012 No : OR=2.08; p=0.143 ARN-HIV CNS penetration score: p<0.001 *baseline ARN-HIV was not systematically available HAND in HAART Era Occurs at higher CD4 counts Course stable or oscillating Occurs with undetectable plasma VL Letendre et al, 16th CROI 2009, Abstract 484b p=0.627

CNS score Does CNS penetration profile matter? 12 10 8 6 4 2 0 3Q ihds Beck-D NO effect on 3Q, ihds or depression Sacktor N, 2001: no effect on cognitive function Cysique L, 2004: effect only in cognitively impaired Marra C., 2009 ~ CNS penetration associated with lower CSF HIV RNA but worse cognitive performance Letendre S., 2007 ~ new index of penetration From JC McArthur, MBBS, MPH, at 13th Annual Ryan White HIV/AIDS Program Clinical Conference, IAS USA.

Correlations of NCI variation by screening tests P<0.001 P=0.<0.001 Δ3Q ΔiHDS P=0.024 P=0.042 Δ ihds Δ 3Q P=0.002 P=0.019 Age P=0.011 HTA Depression/ Beck inventory Adult group Δ Depression/ Beck inventory Pediatric group

Discussions Limits: Shotcoming of more comprehensive reference NP tests Low performance of screening instrument as ihds (Brunett J, 2013). Deepening investigations as HIV-VL in CSF, MRI or complex NC tests were achieved by few of our patients. The reasons for incomplete protocol: High costs of MRI; Difficulties to obtain the consent for lumbar puncture; Refuse to go in other setting to be hospitalized. Challenges for improving early detection of HAND: To use biomarkers for detection of predisposition, diagnostic and monitoring; To develop more accurate NP tests.

Conclusions 1. The frequency of NCD according 2 screening tests is 44% (3Q) and 48% (ihds), consistent with other studies (Heaton, 2010). 2. Along the 4 years, screening tests mark the progression of NCD. 3. Most patients with NCD have mild dysfunctions. 4. The adult group is more severe affected due to the old age and more frequent hypertension, while the pediatric group seems to be faster impaired. 5. The results of NC screening tests are not influenced by HIV current markers or CNS penetration score. 6. IHDS score correlates with nadir CD4, as a hallmark of neurological damages established before initiation ARVT. 7. Mild cognitive impairment associated with HIV requires to improve screening tools and treatment interventions in order to improve the care and the quality of life for individuals living with HIV and AIDS.

References Sacktor NC, Wong M, Nakasujja N et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS,2005; 19(13): 1367-1374. Antinori et al. Proposed decision-tree for diagnosing HIV-associated Neurocognitive Disorders. Neuropsychol Rev. 2009 June; 19(2): 152 168. Brunett Jason, Adriana Carvalhal, Jennifer A. McCombee, et al. Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature AIDS 2013, 27:2385 2401. Letendre S. Central Nervous System Complications in HIV Disease: HIVAssociated Neurocognitive Disorder. Topics in Antiviral Medicine, 2011; 19(4): 137-142. Clifford DB, Ances BM. HIV-Associated Neurocognitive Disorder (HAND). The Lancet infectious diseases. 2013;13(11):976-986. doi:10.1016/s14733099(13)70269-x.

Thank you! Galati, Danube River